ENPP1-IN-2 is a potent Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) inhibitor with an IC50 value of 32.38 nM for recombinant human ENPP-1. ENPP1-IN-2 has anti-tumor activity[1].
ENPP1-IN-2 (compound 015) (50 mg/kg; IP; BID, for 31 days) significantly inhibits tumor growth[1].
| Animal Model: | Female C57BL/6 mice (4-6 weeks; implanted subcutaneously with 2×105 MC38 cells)[1] |
| Dosage: | 50 mg/kg |
| Administration: | IP; BID, for 31 days (given a single 10 Gy exposure of focal radiation to the tumor site) |
| Result: | Significantly inhibited tumor growth. |